ResearcherSun Yat-sen UniversityNo recent work listed

Le Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5276-6468; OpenAlex author ID A5100717197. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 3

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yi Ba · 2 shared papers, 2019–2023 · strength 0.35
- Paper Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. DOI 10.1002/cai2.60 ↗
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Rui Liu · 1 shared paper, 2023 · strength 0.26
- Paper Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. DOI 10.1002/cai2.60 ↗
De‐Shen Wang · 2 shared papers, 2012–2019 · strength 0.12
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
- Paper Are risk factors associated with outcomes in pancreatic cancer? DOI 10.1371/journal.pone.0041984 ↗
Rui‐Hua Xu · 2 shared papers, 2012–2019 · strength 0.12
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
- Paper Are risk factors associated with outcomes in pancreatic cancer? DOI 10.1371/journal.pone.0041984 ↗
Ting Deng · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Zhi‐Qiang Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Fei Zhang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Feng‐Hua Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Wei Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Yuhong Li · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Dong-sheng Zhang · 1 shared paper, 2012 · strength 0.03
- Paper Are risk factors associated with outcomes in pancreatic cancer? DOI 10.1371/journal.pone.0041984 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.